The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | Future directions for APOBEC studies
Reuben Harris, PhD of University of Minnesota, Minneapolis, MN discusses future directions for APOBEC studies. Dr Harris’ laboratory is interested in understanding the APOBEC mechanism in order to reveal some clinical vulnerabilities. In addition, Dr Harris collaborates with others to target evolvability and shut off APOBEC-3B or APOBEC-3H to ultimately slow down tumor mutation rate and improve clinical outcomes. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
